Terrance Mcguire has bought stock on 4 days since Apr 2019
Director at Invivyd, Inc., and 5 other companies
SEC CIK 0001117003 · Filings on SEC.gov ↗
Terrance Mcguire's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Companies
Every filing
8 filings since Dec 2016, newest first
Invivyd, Inc.
Director
Alector, Inc.
Director and 10% owner
Adagio Therapeutics, Inc.
Director
Cyclerion Therapeutics, Inc.
Director
Seer, Inc.
Director
Alector, Inc.
Director and 10% owner
Cyclerion Therapeutics, Inc.
Director
Acceleron Pharma Inc
Director
About Terrance Mcguire
Terrance Gerard McGuire is a Person—an American venture capitalist and founding partner of Polaris Partners, a venture capital firm he co‑founded in 1996 that has managed roughly $4 billion in assets and invested in more than 200 healthcare and technology companies worldwide.( He has served on numerous public and private company boards, including biopharmaceutical and life‑science firms such as Invivyd, Inc., Alector, Seer, Tectonic Therapeutics, Ironwood Pharmaceuticals, Acceleron Pharma, and others.(
McGuire currently serves as a Director on the board of Invivyd, Inc., a biopharmaceutical company focused on protection from serious viral infectious diseases, where he is a corporate insider and has reported multiple equity transactions, including grants and sales of Invivyd stock options and shares under SEC Form 4 filings.( Beyond Invivyd, his career highlights include more than 35 years of early‑stage investing leadership at Polaris Partners and board roles at prominent healthcare and technology companies such as Adimab, Seer, Tectonic Therapeutics, Alector, Akamai, and Cubist Pharmaceuticals.( McGuire holds an MBA from Harvard Business School, an MS in engineering from Dartmouth’s Thayer School of Engineering, and a BS in physics and economics from Hobart College, reflecting a strong technical and financial foundation for his work in venture capital and life‑science governance.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.